• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TALAZOPARIB Drug Record

  • Summary
  • Interactions
  • Claims
  • TALAZOPARIB chembl:CHEMBL3137320 ApprovedAntineoplastic

    Alternate Names:

    BMN 673
    BMN-673
    TALAZOPARIB
    LT-673

    Drug Info:

    (5 More Sources)

    Publications:

    de Bono et al., 2017, Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers., Cancer Discov
    Mo et al., 2016, mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer., Clin. Cancer Res.
    Shen et al., 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency., Clin. Cancer Res.
    Sulkowski et al., 2017, 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity., Sci Transl Med
    Wang B et al., 2016, Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent., J Med Chem
    Wu S et al., 2020, <i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma., Clin Cancer Res
    Fejzo et al., 2017, Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi., Genes Chromosomes Cancer
    Lok BH et al., 2017, PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer., Clin Cancer Res
  • TALAZOPARIB   SLFN11

    Interaction Score: 3.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27440269


    Sources:
    CIViC

  • TALAZOPARIB   PSMD4

    Interaction Score: 2.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28316110


    Sources:
    CIViC

  • TALAZOPARIB   PARP2

    Interaction Score: 1.61

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Poly [ADP-ribose] polymerase 2 inhibitor

    PMIDs:
    26652717


    Sources:
    ChemblInteractions

  • TALAZOPARIB   BRCA2

    Interaction Score: 1.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type decreased response
    Approval Status Phase I

    PMIDs:
    28242752 26546619 23881923


    Sources:
    JAX-CKB CIViC PharmGKB OncoKB

  • TALAZOPARIB   PARP1

    Interaction Score: 0.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Poly [ADP-ribose] polymerase-1 inhibitor
    Direct Interaction yes

    PMIDs:
    26652717


    Sources:
    ChemblInteractions

  • TALAZOPARIB   BRCA1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26546619 28242752 23881923


    Sources:
    JAX-CKB CIViC PharmGKB OncoKB

  • TALAZOPARIB   ATM

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    23881923


    Sources:
    JAX-CKB

  • TALAZOPARIB   PTEN

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    23881923


    Sources:
    JAX-CKB

  • TALAZOPARIB   ERBB2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • TALAZOPARIB   EGFR

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31852834


    Sources:
    CIViC

  • TALAZOPARIB   IDH1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colon carcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    28148839


    Sources:
    JAX-CKB

  • JAX-CKB: Talazoparib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Shen et al., 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency., Clin. Cancer Res.
    Mo et al., 2016, mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer., Clin. Cancer Res.
    de Bono et al., 2017, Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers., Cancer Discov

  • CIViC: TALAZOPARIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    de Bono et al., 2017, Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers., Cancer Discov
    Wu S et al., 2020, <i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma., Clin Cancer Res
    Lok BH et al., 2017, PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer., Clin Cancer Res

  • TTD: Talazoparib

    • Version: 2020.06.01

    Alternate Names:
    D0GV8J TTD Drug ID

    Drug Info:

    Publications:

  • TTD: BMN-673

    • Version: 2020.06.01

    Alternate Names:
    D0X5LR TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3137320

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: talazoparib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3137320

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Talazoparib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Talazoparib

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21